Breaking Finance News

Zacks Investment Research upgraded Neovasc Inc (US) (NASDAQ:NVCN) to Hold in a report released today.

Zacks Investment Research has upgraded Neovasc Inc (US) (NASDAQ:NVCN) to Hold in a report released on 01/12/2017.

Just yesterday Neovasc Inc (US) (NASDAQ:NVCN) traded -3.08% lower at $1.88. Neovasc Inc (US)’s 50-day moving average is $1.49 and its 200-day moving average is $0.78. The last stock price is up 142.98% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.05% over the same time period. 0 shares of NVCN traded hands, down from an average trading volume of 5,479,540

Recent Performance Chart

Neovasc Inc (US) (NASDAQ:NVCN)

Neovasc Inc (US) has 52 week low of $0.37 and a 52 week high of $4.94 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 3 brokerages have issued a ratings update on the company. The average stock price target is $9.51 with 0 brokerages rating the stock a strong buy, 0 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Neovasc Inc (US) (NASDAQ:NVCN)

Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.